| Literature DB >> 21512644 |
Karen Bieback1, Katharina Schallmoser, Harald Klüter, Dirk Strunk.
Abstract
SUMMARY: Multipotent mesenchymal stromal cells (MSCs) are currently exploited in numerous clinical trials to investigate their potential in immune regulation, hematopoiesis, and tissue regeneration. The low frequency of MSCs necessitates cell expansion to achieve transplantable numbers. The challenge is to assure safe and high-quality cell production. GMP(Good Manufacturing Practice)-graded cell processing such as cell preparation, culture, and manipulation is mandatory for the progress of such advanced cell therapy. This review summarizes protocols to isolate MSCs from bone marrow and adipose tissue and to expand MSCs for clinical use focussing on culture media composition as well as culture devices and assays to ensure and control quality of the final product.Entities:
Year: 2008 PMID: 21512644 PMCID: PMC3076361 DOI: 10.1159/000141567
Source DB: PubMed Journal: Transfus Med Hemother ISSN: 1660-3796 Impact factor: 3.747